Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Influenza, Human 1Hematologic Neoplasms 1

Interventions

Influenza Vaccines 13trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2Vaccines 2Oseltamivir 2FluMist 2Cyclophosphamide 2vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Starch 1SARS-CoV-2 inactivated vaccines 1Rituximab 1Nivolumab 1Melphalan 1Levetiracetam 1Lenalidomide 1Ipilimumab 1Interferons 1Interferon alpha-2 1Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluzone High-Dose 1Diphtheria-Tetanus Vaccine 1Celecoxib 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Influenza, Human × baloxavir × Clear all
NCT04712539 2026-02-11

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Influenza, Human, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡